BSF Enterprise's 3D Bio-Tissues Signs Five-Year Supply Agreement with SeaWith for Cultivated Meat

BSF Enterprise inks five-year City-Mix supply deal with South Korea’s SeaWith

BSF Enterprise’s subsidiary, 3D Bio-Tissues (3DBT), has signed a five-year commercial supply agreement with SeaWith, a South Korean cultivated meat innovator. The deal centres on City-Mix, 3DBT’s proprietary macromolecular crowder that boosts cell culture efficiency.

Headline numbers are modest but meaningful: the agreement is estimated to be worth approximately £300,000 over the term. More importantly, it places City-Mix into the production pipeline for SeaWith’s flagship Welldone cultivated beef product and supports a phased scale-up of supply volumes through 2030.

The moving parts: what is City-Mix and why does it matter?

City-Mix is described as a premium macromolecular crowder. In plain English, it is an additive that makes cells grow more efficiently in a lab setting, which is crucial for cultivated meat producers trying to scale up without costs spiralling.

The RNS states that City-Mix is expected to significantly lower production costs for SeaWith by reducing the requirement for expensive growth media by approximately 30%. Growth media is one of the costliest inputs in cultivated meat. If City-Mix can reliably cut that bill, it directly improves unit economics and strengthens the case for commercial roll-out.

Key terms at a glance

Counterparty	SeaWith (South Korea)
Product supplied	City-Mix (macromolecular crowder)
Contract length	Five years
Estimated value to 3DBT	Approximately £300,000 over the term
Use case	Supports SeaWith’s Welldone cultivated beef production pipeline
Cost impact	\~30% reduction in growth media requirement (expected)
Scale-up path	Phased supply ramp through 2030 aligned with SeaWith’s large-scale facilities

Why this is strategically useful for BSF shareholders

First, it is another commercial validation point for City-Mix in the global cultivated protein market. This is not a one-off trial or a narrow pilot. It is a five-year supply framework that embeds 3DBT’s tech into an active production pipeline.

Second, the geography matters. SeaWith is operating within South Korea’s Gyeongbuk Cell-Cultured Food Regulatory Free Zone. That signals a government-supported environment and makes South Korea an attractive early-market for cultivated foods. Having City-Mix in the toolkit of a designated operator in that zone is a strong reference position for 3DBT across Asia.

Third, even though approximately £300,000 over five years is not a game-changing revenue line for a listed company, it is recurring by design and tied to SeaWith’s scaling plans. If SeaWith’s ramp proceeds as envisaged, the supply volumes should increase through 2030.

About SeaWith: credible partner in a supportive ecosystem

SeaWith was founded in 2019 and has raised over $8 million in venture funding. Its technology leans on seaweed-derived processes, with a focus on scalability and environmental impact reduction. The company’s status as a designated operator in South Korea’s regulatory free zone underscores its leadership profile in cultivated foods.

From 3DBT’s perspective, this reduces counterparty risk versus a pre-revenue lab project and anchors City-Mix within a programme that is already interfacing with a defined regulatory framework.

Commercial shape and the signals it sends

To be clear, the RNS estimates the deal value at approximately £300,000 over the term and does not disclose volume commitments, pricing tiers, or margin. It does confirm a regular supply arrangement and a phased scale-up aligned to SeaWith’s transition to large-scale facilities. That is important: it ties City-Mix demand growth to tangible production milestones, not just R&D activity.

City-Mix’s expected ~30% reduction in growth media requirement is the standout claim. If realised at production scale, that is a compelling differentiator for 3DBT’s technology and a practical lever for SeaWith’s cost base as it moves from pilot to commercial runs.

Caveats and what to watch next

• Contract size: Approximately £300,000 over five years is relatively small. Investors should view this as a beachhead deal and a reference customer in Asia, not a revenue transformer.
• Disclosure gaps: The RNS does not disclose delivery cadence, minimum order quantities, or gross margin. Revenue phasing is also not disclosed.
• Execution dependency: The scale-up plan runs through 2030 and is linked to SeaWith’s facility transition. If SeaWith encounters delays, City-Mix volumes could lag.
• Validation at scale: The 30% media reduction is an expectation. Monitoring real-world performance as SeaWith ramps will be key.

Where this fits within BSF Enterprise’s broader story

BSF Enterprise develops and commercialises tissue-engineered solutions across multiple verticals, including lab-grown leather (via LGL), cultivated meat, and corneal repair. City-Mix is a enabling product within that portfolio, designed to improve the efficiency of cell culture across applications.

This agreement with SeaWith extends City-Mix’s footprint into a high-potential cultivated meat market and adds a multi-year commercial pillar to 3DBT’s activities. It is a sensible, strategic step that could open doors to further contracts if performance and cost savings track expectations.

My take: a practical win with asymmetric optionality

This is a solid, execution-focused announcement. The guaranteed headline revenue is limited, but the optionality is attractive. If SeaWith’s ramp stays on course and City-Mix delivers the touted media-use reduction, 3DBT secures a growing, repeat customer in a market with supportive policy foundations.

On balance, I view it as modestly positive today with the potential to become more material over time. The watch items are volume ramps, disclosed performance data in production settings, and any follow-on agreements that use this as a case study.

Investor resources and contacts

• Engage with management and investor Q&A: https://bsfenterprise.com/link/Pqnkoy
• Share questions on this announcement: https://bsfenterprise.com/s/a1f22b
• Subscribe to BSF news alerts: https://bsfenterprise.com/s/bb9f43

Company and broker details

• BSF Enterprise PLC (LSE: BSFA) – ISIN: GB00BHNBDQ51, SEDOL: BHNBDQ5
• Chairman: Geoff Baker
• CEO & Director: Che Connon
• Shard Capital (Broker): Damon Heath, Isabella Pierre – +44 (0)20 4530 6926 / +44 (0)20 4530 6928